Major cardiac surgery for coronary heart disease and valve defects
Conditions
Interventions
Group 1: Patients undergoing major open cardiac surgery
After verbal and written consent is obtained, clinical data (diagnosis, medical history, chronic medication, results of instrumental examinatio
Sponsors
Universitätsmedizin Göttingen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Age over 18 years • Capacity to consent before surgery • Ability to receive information and give consent before surgery • Open-heart surgery • Surgeries with and without a heart-lung machine
Exclusion criteria
Exclusion criteria: • Condition after resuscitation • Patients with end-stage renal failure (eGFR 3 or EF < 25) • Patients with liver cirrhosis (Child-Pugh groups B and C, typically significantly elevated serum bilirubin and prolonged INR) • Patients with clinically relevant congenital heart defects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Plasma concentration of biomarkers (carnitine derivatives, tryptophan derivatives, L-citrulline, L-arginine, and other metabolites from energy, protein, and fat metabolism) before, within the first 24 hours, and after 3 to 6 days following cardiac surgery. 2. Inherited genomic variants and non-genetic parameters (mRNA expression, DNA methylation in peripheral blood) of enzymes involved in catecholamine, lipid, and amino acid metabolism, and of transport proteins in the liver and kidney. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Catecholamine dosages intraoperatively and postoperatively 2. Return of spontaneous breathing and extubation time 3. Early postoperative organ dysfunction | — |
Countries
Germany
Contacts
Public ContactAlexandra Sachkova
Universitätsmedizin Göttingen, Institut für Klinische Pharmakologie
Outcome results
None listed